Recent advances in low-concentration Atropine for controlling myopia progression
10.3980/j.issn.1672-5123.2022.6.19
- VernacularTitle:低浓度阿托品控制近视的临床研究进展
- Author:
Kun Zhou
1
Author Information
1. 1Department of Ophthalmology, Xi'an No.1 Hospital;Shaanxi Institute of Ophthalmology;Shaanxi Key Laboratory of Ophthalmology;Department of Ophthalmology, the First Affiliated Hospital of Northwestern University;Clinical Research Center for Ophthalmology Diseases of Shaanxi Province, Xi'an 710002, Shaanxi Province, China|2Eye Hospital of Wenzhou Medical University;Glaucoma Research Institute, Wenzhou Medical University, Wenzhou 325027, Zhejiang Province, China
- Publication Type:Review
- Keywords:
myopia;
myopia control;
low-concentration Atropine;
axis;
child;
adolescent
- From:
International Eye Science
2022;22(6):977-980
- CountryChina
- Language:Chinese
-
Abstract:
As the prevalence of myopia continues to increase, our society shows increasing interest in the visual impairment associated with myopia and methods for myopia control. Current methods for myopia control include atropine, orthokeratology, dual-focus contact lenses, multifocal contact lenses, and functional frame glasses, etc. Low-concentration atropine(0.01%, 0.05%)became the first-line medication which has been administrated and shown to be effective in controlling the occurrence and progression of myopia. Meanwhile, low-concentration atropine shows longer-lasting effects, less frequent adverse effects and higher patients' acceptance than high-concentration atropine. This article reviews the efficacy, safety, time-to-treatment, and effects when combined with other treatments to provide evidence for the clinical application of low-concentration atropine on myopia control.
- Full text:202206019.pdf
